Published in Proc Natl Acad Sci U S A on November 19, 2004
Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol (2012) 1.90
Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84
Allosteric modulation of DNA by small molecules. Proc Natl Acad Sci U S A (2009) 1.61
Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58
Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res (2006) 1.55
Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets (2010) 1.49
Specificity landscapes of DNA binding molecules elucidate biological function. Proc Natl Acad Sci U S A (2010) 1.39
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med (2009) 1.38
Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A (2009) 1.38
Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A (2011) 1.36
Quantitative microarray profiling of DNA-binding molecules. J Am Chem Soc (2007) 1.30
Next generation hairpin polyamides with (R)-3,4-diaminobutyric acid turn unit. J Am Chem Soc (2008) 1.23
Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc (2009) 1.21
Design and synthesis of a cell-permeable synthetic transcription factor mimic. J Comb Chem (2007) 1.17
Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J Am Chem Soc (2010) 1.15
Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J Am Chem Soc (2009) 1.15
Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta (2012) 1.14
Quantitating the concentration of Py-Im polyamide-fluorescein conjugates in live cells. Bioorg Med Chem Lett (2008) 1.08
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle (2010) 1.07
In vivo imaging of pyrrole-imidazole polyamides with positron emission tomography. Proc Natl Acad Sci U S A (2008) 1.07
Programmable oligomers for minor groove DNA recognition. J Am Chem Soc (2006) 1.06
Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2012) 1.04
Direct inhibition of the DNA-binding activity of POU transcription factors Pit-1 and Brn-3 by selective binding of a phenyl-furan-benzimidazole dication. Nucleic Acids Res (2008) 1.04
Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear. J Am Chem Soc (2012) 1.03
Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer. Clin Cancer Res (2008) 1.02
Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets (2013) 1.01
In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics. Proc Natl Acad Sci U S A (2014) 1.01
Microwave assisted synthesis of Py-Im polyamides. Org Lett (2012) 0.98
Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling. Proc Natl Acad Sci U S A (2013) 0.96
Characterization and solubilization of pyrrole-imidazole polyamide aggregates. J Med Chem (2012) 0.96
Unanticipated differences between alpha- and gamma-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates. Nucleic Acids Res (2006) 0.94
Enhancing the cellular uptake of Py-Im polyamides through next-generation aryl turns. Nucleic Acids Res (2011) 0.93
Alpha-diaminobutyric acid-linked hairpin polyamides. Bioorg Med Chem (2007) 0.92
Activity of a Py-Im polyamide targeted to the estrogen response element. Mol Cancer Ther (2013) 0.92
Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia. Mol Cancer Ther (2008) 0.91
Programmable oligomers targeting 5'-GGGG-3' in the minor groove of DNA and NF-kappaB binding inhibition. Bioorg Med Chem (2006) 0.91
Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry (2011) 0.91
Altered cytokine profiles in patients with Chuvash polycythemia. Am J Hematol (2009) 0.90
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Programmable DNA-binding small molecules. Bioorg Med Chem (2013) 0.89
Solution-phase synthesis of pyrrole-imidazole polyamides. J Am Chem Soc (2009) 0.89
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One (2010) 0.89
Quantitative detection of small molecule/DNA complexes employing a force-based and label-free DNA-microarray. Biophys J (2009) 0.87
Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. Invest New Drugs (2010) 0.86
Pyrrole-imidazole hairpin polyamides with high affinity at 5'-CGCG-3' DNA sequence; influence of cytosine methylation on binding. Nucleic Acids Res (2008) 0.86
CUL2 is required for the activity of hypoxia-inducible factor and vasculogenesis. J Biol Chem (2008) 0.86
Alkylation of template strand of coding region causes effective gene silencing. Nucleic Acids Res (2006) 0.85
A multinodular goiter as the initial presentation of a renal cell carcinoma harbouring a novel VHL mutation. BMC Endocr Disord (2006) 0.85
Modifications at the C-terminus to improve pyrrole-imidazole polyamide activity in cell culture. J Med Chem (2009) 0.85
Synthesis of cyclic Py-Im polyamide libraries. J Org Chem (2012) 0.84
Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit. J Med Chem (2013) 0.83
DNA sequence selectivity of hairpin polyamide turn units. Bioorg Med Chem Lett (2009) 0.82
Mini review: protein-protein interactions in transcription: a fertile ground for helix mimetics. Biopolymers (2011) 0.82
The reach of linear protein-DNA dimerizers. J Am Chem Soc (2007) 0.82
Mapping polyamide-DNA interactions in human cells reveals a new design strategy for effective targeting of genomic sites. Angew Chem Int Ed Engl (2014) 0.82
Expanding the repertoire of natural product-inspired ring pairs for molecular recognition of DNA. Org Lett (2011) 0.82
Targeting Protein-Protein Interactions in the HIF System. ChemMedChem (2016) 0.81
Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). Eur J Med Chem (2014) 0.80
Small-molecule regulators that mimic transcription factors. Biochim Biophys Acta (2010) 0.80
Differential disruption of EWS-FLI1 binding by DNA-binding agents. PLoS One (2013) 0.79
Subtle recognition of 14-base pair DNA sequences via threading polyintercalation. Biochemistry (2012) 0.78
Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers. Biochem J (2014) 0.78
Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. PLoS One (2015) 0.77
Oligomerization route to Py-Im polyamide macrocycles. Org Lett (2009) 0.77
Number of polyploid giant cancer cells and expression of EZH2 are associated with VM formation and tumor grade in human ovarian tumor. Biomed Res Int (2014) 0.76
An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors. Mol Cancer Ther (2015) 0.76
Synthetic genome readers target clustered binding sites across diverse chromatin states. Proc Natl Acad Sci U S A (2016) 0.75
A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity. Mol Cancer Res (2016) 0.75
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer (2002) 5.63
Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Curr Opin Struct Biol (2003) 3.80
Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature (1998) 3.77
Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med (2000) 3.72
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 3.43
The endothelin axis: emerging role in cancer. Nat Rev Cancer (2003) 2.81
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis (2003) 2.68
The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem (1996) 2.30
Regulation of gene expression by small molecules. Nature (1997) 2.27
A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA. Science (1998) 2.05
Footprinting methods for analysis of pyrrole-imidazole polyamide/DNA complexes. Methods Enzymol (2001) 1.97
Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A (1998) 1.96
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. Biotechniques (2004) 1.87
Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res (2004) 1.84
Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol (2003) 1.81
Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A (2003) 1.80
Crystal structures of nucleosome core particles in complex with minor groove DNA-binding ligands. J Mol Biol (2003) 1.63
Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci U S A (1998) 1.50
How oxygen makes its presence felt. Genes Dev (2002) 1.45
Solid-phase synthesis of DNA binding polyamides on oxime resin. Bioorg Med Chem (2002) 1.45
Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ (1998) 1.44
Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem (1999) 1.41
Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem (1996) 1.41
Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem (1997) 1.33
HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res (1999) 1.29
Molecular recognition of the nucleosomal "supergroove". Proc Natl Acad Sci U S A (2004) 1.25
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther (2002) 1.11
Shape selective recognition of T.A base pairs by hairpin polyamides containing N-terminal 3-methoxy (and 3-chloro) thiophene residues. Bioorg Med Chem (2003) 1.10
Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem (2004) 1.06
Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun (2003) 1.05
Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. J Clin Endocrinol Metab (2003) 0.97
Inhibition of DNA binding by NF-kappa B with pyrrole-imidazole polyamides. Biochemistry (2002) 0.97
Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter. J Biol Chem (1998) 0.91
Hypoxia response elements. Oncol Res (1997) 0.91
Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep (2011) 0.90
Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer (2002) 0.87
Mammalian oxygen sensing and hypoxia inducible factor-1. Int J Biochem Cell Biol (1997) 0.85
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A (2002) 4.03
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (2002) 3.86
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature (2004) 3.63
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Defining the sequence-recognition profile of DNA-binding molecules. Proc Natl Acad Sci U S A (2006) 2.97
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98
Q&A: Cancer: clues from cell metabolism. Nature (2010) 1.98
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol (2007) 1.92
Arresting cancer proliferation by small-molecule gene regulation. Chem Biol (2004) 1.90
The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol (2012) 1.90
Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res (2004) 1.84
Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84
Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol (2003) 1.81
Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A (2003) 1.80
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep (2002) 1.71
DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci U S A (2006) 1.70
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res (2003) 1.67
Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. J Clin Invest (2011) 1.66
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis (2004) 1.64
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood (2012) 1.64
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol (2009) 1.63
Crystal structures of nucleosome core particles in complex with minor groove DNA-binding ligands. J Mol Biol (2003) 1.63
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol (2007) 1.62
Allosteric modulation of DNA by small molecules. Proc Natl Acad Sci U S A (2009) 1.61
Reactivation of hepatic EPO synthesis in mice after PHD loss. Science (2010) 1.60
A role for mammalian Sin3 in permanent gene silencing. Mol Cell (2008) 1.59
Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev (2003) 1.56
Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res (2006) 1.55
Cellular uptake of N-methylpyrrole/N-methylimidazole polyamide-dye conjugates. Bioorg Med Chem (2002) 1.52
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest (2009) 1.49
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell (2007) 1.47
Solid-phase synthesis of DNA binding polyamides on oxime resin. Bioorg Med Chem (2002) 1.45
pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol (2004) 1.45
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology (2002) 1.45
Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood (2015) 1.39
Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A (2009) 1.38
Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med (2004) 1.37
Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A (2011) 1.36
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
Quantitative microarray profiling of DNA-binding molecules. J Am Chem Soc (2007) 1.30
Repeated neonatal handling with maternal separation permanently alters hippocampal GABAA receptors and behavioral stress responses. Proc Natl Acad Sci U S A (2003) 1.28
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A (2011) 1.28
Molecular recognition of the nucleosomal "supergroove". Proc Natl Acad Sci U S A (2004) 1.25
Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol (2002) 1.24
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med (2003) 1.23
Next generation hairpin polyamides with (R)-3,4-diaminobutyric acid turn unit. J Am Chem Soc (2008) 1.23
Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc (2009) 1.21
Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation (2010) 1.20
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol (2006) 1.16
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol (2002) 1.16
Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J Am Chem Soc (2010) 1.15
Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2013) 1.13
Sequence specific fluorescence detection of double strand DNA. J Am Chem Soc (2003) 1.11
Blocking transcription through a nucleosome with synthetic DNA ligands. J Mol Biol (2002) 1.11
Shape selective recognition of T.A base pairs by hairpin polyamides containing N-terminal 3-methoxy (and 3-chloro) thiophene residues. Bioorg Med Chem (2003) 1.10
Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays. Anal Chem (2009) 1.10
Small molecule transcription factor mimic. J Am Chem Soc (2004) 1.10
Design of artificial transcriptional activators with rigid poly-L-proline linkers. J Am Chem Soc (2002) 1.09
Role of mismatch repair enzymes in GAA·TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells. J Biol Chem (2012) 1.09
Quantitating the concentration of Py-Im polyamide-fluorescein conjugates in live cells. Bioorg Med Chem Lett (2008) 1.08